On-demand: featuring presentation and speaker Q&A: Developed for healthcare professionals and researchers working with Cancer of Unknown Primary (CUP). Take one hour to join the world-leading authority on CUP - Dr F Anthony Greco – discussing how leading edge research is transforming therapeutic options for CUP patients:
Thank you to the webinar sponsor: Cancer of Unknown Primary Foundation - Jo's Friends
Watch this online NHS event from the comfort of your own home
Join world-leading CUP authority Dr F Anthony Greco (US) taking a long view of the challenges of developing CUP research and treatment. Benefit from:
Welcome
John Symons, Director, CUP Foundation - Jo's friends
|
|
Interlocutor’s opening remarks
Dr Harpreet Wasan, Consultant Oncologist, Imperial College Healthcare NHS Trust
|
|
Cancer of Unknown Primary: Is the unknown now known?
Dr Harpreet Wasan, Consultant Oncologist, Imperial College Healthcare NHS Trust in conversation with Dr Anthony Greco, Medical Oncologist, Tennessee Oncology
|
|
Question and answer session
Dr Harpreet Wasan, Consultant Oncologist, Imperial College Healthcare NHS Trust and Dr Anthony Greco, Medical Oncologist, Tennessee Oncology
|
|
Close of webinar
|
First-hand speaker experiences
Dr Harpreet S. Wasan MBBS FRCP is Consultant and Reader in Medical Oncology, Department of Cancer Medicine, Imperial College NHS Trust. He leads the gastrointestinal clinical research program at Hammersmith Hospital, and is the current Lead for Cancer for The N.W London NIHR Research Network. He is the chief investigator of the completed national CRUK/NIHR study for cancer of unknown primary (CUP-ONE), which is comparing rapid molecular diagnostics (with over 600 patients); and the NSHE 100k genome GeCip domain lead for CUP. He is an Advisory Board Member for The CUP Foundation, helped develop Macmillan patient information, and invited to give support for the original NICE CUP guidelines. He has recently started an immunotherapy study (CUPEM) for CUP patients and is involved as UK-CI in a tumour mutational burden (TMB) study, which includes CUP patients.
Dr F. Anthony Greco MD is Co-Founder of the Sarah Cannon Research Institute located in Nashville, USA. Dr. Greco’s principal professional interest has been clinical cancer research and he now specialises in cancers of unknown primary origin, lung cancer and germ cell tumors. He has helped to define the complex group of patients with unknown primary cancer recognizing many subsets of patients requiring specific therapy. He has developed, or helped develop, new and improved therapies for patients with several types of neoplastic diseases, including unknown primary cancer.